A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Luckily for you, we built StockStory to help you separate the good from the bad. Keeping that in mind, here are three cash-producing companies to avoid and some better opportunities instead.
Tractor Supply (TSCO)
Trailing 12-Month Free Cash Flow Margin: 6.2%
Started as a mail-order tractor parts business, Tractor Supply (NASDAQ: TSCO) is a retailer of general goods such as agricultural supplies, hardware, and pet food for the rural consumer.
Why Is TSCO Not Exciting?
- Sizable revenue base leads to growth challenges as its 4.4% annual revenue increases over the last three years fell short of other consumer retail companies
- Lagging same-store sales over the past two years suggest it might have to change its pricing and marketing strategy to stimulate demand
- Gross margin of 36.4% is an output of its commoditized inventory
At $51.37 per share, Tractor Supply trades at 22.8x forward P/E. Dive into our free research report to see why there are better opportunities than TSCO.
La-Z-Boy (LZB)
Trailing 12-Month Free Cash Flow Margin: 5.9%
The prized possession of every mancave, La-Z-Boy (NYSE: LZB) is a furniture company specializing in recliners, sofas, and seats.
Why Do We Think LZB Will Underperform?
- Muted 5.8% annual revenue growth over the last five years shows its demand lagged behind its consumer discretionary peers
- Free cash flow margin is expected to remain in place over the coming year
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
La-Z-Boy is trading at $37.77 per share, or 13.4x forward P/E. Check out our free in-depth research report to learn more about why LZB doesn’t pass our bar.
Corcept (CORT)
Trailing 12-Month Free Cash Flow Margin: 22%
Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ: CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.
Why Does CORT Fall Short?
- Efficiency has decreased over the last five years as its adjusted operating margin fell by 24.7 percentage points
- Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 6.5% annually
- Free cash flow margin shrank by 21.3 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
Corcept’s stock price of $82.51 implies a valuation ratio of 95.3x forward P/E. If you’re considering CORT for your portfolio, see our FREE research report to learn more.
Stocks We Like More
The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today.
